Boots has launched a private medical cannabis service for eligible adults living with chronic pain, generalised anxiety disorder or insomnia, bringing one of Britain’s best-known pharmacy names into specialist treatment.
Its online service, SureLeaf, is for people aged 25 and over who have tried conventional treatments without adequate relief. A prescription is not automatic: a specialist consultant assesses each patient, and a multidisciplinary team including a second independent consultant reviews any proposed prescription, Boots said.
Who can apply?
Boots lists eligible pain conditions including fibromyalgia, neuropathic pain, chronic back or neck pain, arthritis, chronic migraine and endometriosis-related pelvic pain. Applicants start online; those considered suitable proceed to a video consultation with a consultant on the General Medical Council specialist register.
If treatment begins, Boots says patients will be reviewed after 28 days and at least every three months. The service is private, not an NHS prescription. Pharmacy Magazine reports that the annual service costs £99 for an initial assessment and four follow-up consultations; medication and extra appointments cost more. It also reports an £89 one-month trial. Patients should check the full costs before proceeding.
What does the evidence say?
The NHS says there is some evidence that medical cannabis can help certain types of pain, but not enough to recommend it for pain relief. Very few people in England are likely to get an NHS prescription, with use generally limited to certain severe epilepsy syndromes, chemotherapy-related nausea and vomiting, or multiple sclerosis-related spasticity when other treatments have not helped or are unsuitable.
NHS England says there is no legal restriction on the conditions for which cannabis-based products may be prescribed, but clinicians must consider the evidence, patient circumstances and other medicines. Most products are unlicensed and specialist oversight is required. The NHS notes potential risks associated with THC, including an increased risk of psychotic illness in some people.
Boots says it is exploring a research collaboration with the University of Nottingham on chronic pain outcomes and prescribing. The programme is under consideration, not a completed study.
The launch does not legalise recreational cannabis. Patients considering treatment should discuss their circumstances, risks and alternatives with a qualified clinician.











